FDA Review Trends: Original PMAs Up, 510(k)s Down So Far In 2015
This article was originally published in The Gray Sheet
Executive Summary
The overall volume of agency approvals and clearances has been relatively steady from last year to this year. The biggest spike so far is in original PMA approvals.
You may also be interested in...
Medtronic’s CoreValve Makes Strides In Japan And U.S.
The Japanese regulatory authority has approved Medtronic’s CoreValve transcatheter aortic valve based on data from the CoreValve Japan trial and U.S. trial data. Meanwhile, FDA granted CoreValve its first TAVR approval for a "valve-in-valve" indication for patients with prior replacements.
Successful De Novo Petitions Double With Advent Of Direct Route
FDA granted more than double the number of de novo petitions in FY 2013 compared to past years, reflecting the availability of the direct de novo pathway recently established by Congress. De novo petitions allow a device that FDA deems to be low-to-moderate risk but without a clear predicate to enter the market without requiring a PMA.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.